查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1941548

生物相似藥市場規模、佔有率和趨勢分析報告：按藥物類別、適應症、最終用途、地區和細分市場預測（2026-2033 年）

Biosimilars Market Size, Share & Trends Analysis Report By Drug Class, By Indication, By End Use, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

生物相似藥市場概述

2025年全球生物相似藥市場規模估計為395.9億美元，預計2033年將達到1,515.8億美元。

預計從 2026 年到 2033 年，該市場將以 18.44% 的複合年成長率成長。生物相似藥的成本效益和全球慢性病盛行率的不斷上升是推動市場成長的主要因素。

由於生物相似藥的研發相對容易，與新型生物製藥相比，其研發投入較少，卻能達到類似的臨床療效，因此市場持續成長。更短的研發週期和更高的生產效率意味著更低的生產成本，使製造商能夠提供具有競爭力的價格和可觀的利潤率。隨著已開發市場和新興市場對具成本效益生物製藥療法的需求不斷成長，製造商正日益將策略重點轉向生物相似藥，以提高其產品組合的盈利。雖然生物相似藥在輔料和製劑成分方面可能存在細微差異，但其評估標準是與參考生物製藥在安全性、純度和療效方面不存在具有臨床意義的差異，這支持了生物相似藥在各個治療領域的廣泛應用。

法規結構在建立信任和加速市場滲透方面發揮核心作用。美國食品藥物管理局(FDA) 要求生物相似藥申請人通過詳細的分析表徵、藥物動力學比較以及必要的臨床證據，證明其產品與參考生物製藥具有高度相似性。這些監管流程旨在確保病患安全，同時避免不必要的臨床試驗重複，從而降低研發風險和成本。這種嚴格而有效率的核准流程增強了醫生和支付方對生物相似藥的信任，有助於其在腫瘤學、免疫學和慢性病管理領域獲得市場佔有率。

2025年一個顯著的商業案例印證了這一趨勢，即安進公司在美國推出的Weslana，它是Stelara的參考生物類似藥，自體免疫疾病。此次上市標誌著高價值免疫學生物類似藥發展的重要里程碑，也展現了安進公司在複雜的單株抗體領域競爭的能力。 Weslana的上市預計將改善皮膚病學和胃腸病學治療的經濟效益，同時加劇Ustekinumab市場的價格競爭，從而推動2025年生物相似藥整體收入的成長。

監管核准的增加和投資活動的活性化進一步凸顯了市場的成熟度。近年來，美國FDA已核准了多種腫瘤生物類似藥，這些藥物已成功商業性，並持續重塑市場競爭格局。同時，各藥廠也加大研發投入，以強化其未來的產品線。例如，百康生物製藥公司（Biocon Biologics）宣布計劃增加研發支出，以擴大其生物相似藥產品組合，反映出該公司對整個產業長期需求的信心。總而言之，這些進展凸顯了生物相似藥研發和商業化的持續繁榮，為預測期內市場的穩定成長奠定了基礎。

目錄

第1章調查方法和範圍

第2章執行摘要

第3章 生物相似藥市場變數、趨勢與範圍

  • 市場體系展望
  • 市場動態
  • 商業環境分析
    • 產業分析—波特五力分析
    • PESTLE分析
    • 管道分析

第4章 生物相似藥市場：依藥物類別分類的商業分析

  • 按藥物類別分類的市場佔有率（2025 年和 2033 年）
  • 按藥物類別分類的市場規模、預測和趨勢分析（2021-2033 年）
  • 單株抗體（mAbs）
  • 生長因子和造血因子
  • 胰島素及其類似物
  • 骨質疏鬆症/骨骼代謝藥物
  • 其他

第5章 生物相似藥市場：依適應症分類的業務分析

  • 按適應症分類的市場佔有率（2025 年和 2033 年）
  • 按適應症分類的市場規模、預測和趨勢分析（2021-2033 年）
  • 自體免疫疾病（類風濕性關節炎、發炎性腸道疾病、乾癬、僵直性脊椎炎）
  • 腫瘤科（乳癌、結腸癌、淋巴瘤、肺癌、胃癌）
  • 糖尿病（1 型和 2 型）
  • 眼科疾病（濕性老齡化黃斑部病變、糖尿病黃斑部水腫、視網膜靜脈阻塞）
  • 血液疾病/罕見血液疾病
  • 其他

第6章：生物相似藥市場：依最終用途分類的業務分析

  • 按最終用途分類的市場佔有率（2025 年和 2033 年）
  • 按最終用途分類的市場規模、預測和趨勢分析（2021年至2033年）
  • 醫院
  • 專科藥房
  • 線上和零售通路

第7章 生物相似藥市場：區域估算與趨勢分析

  • 區域市場佔有率分析（2025 年和 2033 年）
  • 區域市場概覽
  • 市場規模及預測趨勢分析（2021-2033）：
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭情勢

  • 參與公司概況
  • 企業市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介/列表
    • Amgen Inc
    • F Hoffman-La Roche Ltd.
    • Sandoz International GmbH
    • Dr. Reddy's Laboratories Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Pfizer Inc.
    • Samsung Biopis
    • Biocon
    • Viatris Inc.
    • Celltrion Healthcare Co., Ltd.
    • AbbVie Inc.
Product Code: 978-1-68038-916-6

Biosimilars Market Summary

The global biosimilars market size was estimated at USD 39.59 billion in 2025 and is projected to reach USD 151.58 billion by 2033, growing at a CAGR of 18.44% from 2026 to 2033. The cost-effectiveness of biosimilar drugs and the prevalence of chronic disorders globally are major factors contributing to market growth.

The market continues to gain momentum as these products are comparatively easier to develop than novel biologics, requiring lower research and development investment while delivering comparable clinical outcomes. Reduced development timelines and manufacturing efficiencies translate into lower production costs, enabling competitive pricing and attractive margins for manufacturers. As demand for cost-effective biologic therapies rises across both developed and emerging markets, producers are increasingly shifting strategic focus toward biosimilars to enhance portfolio profitability. Although biosimilars may exhibit minor differences in excipients or formulation components, they are evaluated to ensure no clinically meaningful differences from reference biologics in terms of safety, purity, and efficacy, supporting their broader adoption across therapeutic areas.

Regulatory frameworks play a central role in building confidence and accelerating market uptake. The U.S. Food and Drug Administration requires biosimilar applicants to demonstrate high similarity to the reference biologic through extensive analytical characterization, pharmacokinetic comparability, and clinical evidence where required. These regulatory pathways are designed to ensure patient safety while avoiding unnecessary duplication of clinical trials, thereby reducing development risk and cost. Such stringent yet efficient approval processes have strengthened physician and payer trust in biosimilars, contributing to expanding market share in oncology, immunology, and chronic disease management.

A notable 2025 commercial instance reinforcing this trend is the U.S. launch of Wezlana by Amgen, a biosimilar referencing Stelara for autoimmune indications. This launch marked a significant milestone in high-value immunology biosimilars, demonstrating manufacturers' ability to compete in complex monoclonal antibody segments. The entry of Wezlana is expected to improve treatment affordability in dermatology and gastroenterology while intensifying price competition within the ustekinumab market, thereby supporting overall biosimilars revenue growth in 2025.

Growing regulatory approvals and investment activity further illustrate the market's maturity. The U.S. FDA approved multiple oncology-related biosimilars in recent years, translating into commercial launches that continue to shape the competitive landscape. In parallel, manufacturers are scaling research and development investments to strengthen future pipelines. For instance, Biocon Biologics announced plans to increase R&D spending to advance its biosimilar portfolio, reflecting industry-wide confidence in long-term demand. Collectively, these developments highlight a sustained boom in biosimilar development and commercialization, positioning the market for steady growth over the forecast period.

Global Biosimilars Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global biosimilars market report based on drug class, indication, end use, and region:

  • Drug Class Outlook (Revenue, USD Billion, 2021 - 2033)
  • Monoclonal Antibodies (mAbs)
  • Growth Factors & Hematopoietic Agents
  • Insulin & Analogues
  • Osteoporosis / Bone Metabolism Agents
  • Others
  • Indication Outlook (Revenue, USD Billion, 2021 - 2033)
  • Autoimmune Disorders (RA, IBD, Psoriasis, Ankylosing Spondylitis)
  • Oncology (Breast, Colorectal, Lymphoma, Lung, Gastric)
  • Diabetes Mellitus (Type 1 & Type 2)
  • Ophthalmic Disorders (Wet AMD, DME, RVO)
  • Hematologic / Rare Blood Disorders
  • Others
  • End Use Outlook (Revenue, USD Billion, 2021 - 2033)
  • Hospitals
  • Specialty Pharmacies
  • Online & Retail Channels
  • Regional Outlook (Revenue, USD Billion, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Indication
    • 1.2.3. End Use
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Biosimilars Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis

Chapter 4. Biosimilars Market: Drug Class Business Analysis

  • 4.1. Drug Class Market Share, 2025 & 2033
  • 4.2. Drug Class Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2021 to 2033 (USD Billion)
  • 4.4. Monoclonal Antibodies (mAbs)
    • 4.4.1. Monoclonal Antibodies (mAbs) Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 4.5. Growth Factors & Hematopoietic Agents
    • 4.5.1. Growth Factors & Hematopoietic Agents Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 4.6. Insulin & Analogues
    • 4.6.1. Insulin & Analogues Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 4.7. Osteoporosis / Bone Metabolism Agents
    • 4.7.1. Osteoporosis / Bone Metabolism Agents Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 4.8. Others
    • 4.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 5. Biosimilars Market: Indication Business Analysis

  • 5.1. Indication Market Share, 2025 & 2033
  • 5.2. Indication Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Billion)
  • 5.4. Autoimmune Disorders (RA, IBD, Psoriasis, Ankylosing Spondylitis)
    • 5.4.1. Autoimmune Disorders (RA, IBD, Psoriasis, Ankylosing Spondylitis) Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 5.5. Oncology (Breast, Colorectal, Lymphoma, Lung, Gastric)
    • 5.5.1. Oncology (Breast, Colorectal, Lymphoma, Lung, Gastric) Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 5.6. Diabetes Mellitus (Type 1 & Type 2)
    • 5.6.1. Diabetes Mellitus (Type 1 & Type 2) Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 5.7. Ophthalmic Disorders (Wet AMD, DME, RVO)
    • 5.7.1. Ophthalmic Disorders (Wet AMD, DME, RVO) Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 5.8. Hematologic / Rare Blood Disorders
    • 5.8.1. Hematologic / Rare Blood Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 5.9. Others
    • 5.9.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 6. Biosimilars Market: End Use Business Analysis

  • 6.1. End Use Market Share, 2025 & 2033
  • 6.2. End Use Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Billion)
  • 6.4. Hospitals
    • 6.4.1. Hospitals Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 6.5. Specialty Pharmacies
    • 6.5.1. Specialty Pharmacies Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 6.6. Online & Retail Channels
    • 6.6.1. Online & Retail Channels Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 7. Biosimilars Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2025 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 7.4. North America
    • 7.4.1. North America Biosimilars Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Billion)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Type Disease Prevalence
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Framework
      • 7.4.2.5. U.S. Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Type Disease Prevalence
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Framework
      • 7.4.3.5. Canada Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Type Disease Prevalence
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Framework
      • 7.4.4.5. Mexico Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.5. Europe
    • 7.5.1. Europe Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Type Disease Prevalence
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Framework
      • 7.5.2.5. UK Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Type Disease Prevalence
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Framework
      • 7.5.3.5. Germany Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Type Disease Prevalence
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement Framework
      • 7.5.4.5. France Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Type Disease Prevalence
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Reimbursement Framework
      • 7.5.5.5. Italy Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Type Disease Prevalence
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Reimbursement Framework
      • 7.5.6.5. Spain Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Type Disease Prevalence
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Reimbursement Framework
      • 7.5.7.5. Denmark Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Type Disease Prevalence
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Reimbursement Framework
      • 7.5.8.5. Sweden Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Type Disease Prevalence
      • 7.5.9.3. Regulatory Framework
      • 7.5.9.4. Reimbursement Framework
      • 7.5.9.5. Norway Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Type Disease Prevalence
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Framework
      • 7.6.2.5. Japan Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Type Disease Prevalence
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Framework
      • 7.6.3.5. China Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Type Disease Prevalence
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Framework
      • 7.6.4.5. India Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Type Disease Prevalence
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Framework
      • 7.6.5.5. Australia Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Type Disease Prevalence
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Reimbursement Framework
      • 7.6.6.5. South Korea Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Type Disease Prevalence
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Reimbursement Framework
      • 7.6.7.5. Thailand Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.7. Latin America
    • 7.7.1. Latin America Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Type Disease Prevalence
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Reimbursement Framework
      • 7.7.2.5. Brazil Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Type Disease Prevalence
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Reimbursement Framework
      • 7.7.3.5. Argentina Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Type Disease Prevalence
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Reimbursement Framework
      • 7.8.2.5. South Africa Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Type Disease Prevalence
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Reimbursement Framework
      • 7.8.3.5. Saudi Arabia Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Type Disease Prevalence
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Reimbursement Framework
      • 7.8.4.5. UAE Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Type Disease Prevalence
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Reimbursement Framework
      • 7.8.5.5. Kuwait Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Amgen Inc
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. F Hoffman-La Roche Ltd.
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Sandoz International GmbH
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Dr. Reddy's Laboratories Ltd.
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Teva Pharmaceutical Industries Ltd.
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Pfizer Inc.
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Samsung Biopis
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Biocon
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Viatris Inc.
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Celltrion Healthcare Co., Ltd.
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives
    • 8.5.11. AbbVie Inc.
      • 8.5.11.1. Overview
      • 8.5.11.2. Financial Performance
      • 8.5.11.3. Product Benchmarking
      • 8.5.11.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List ofabbreviations
  • Table 3 Global biosimilars market, by region, 2021 - 2033 (USD Billion)
  • Table 4 Global biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 5 Global biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 6 Global biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 7 North America biosimilars market, by country, 2021 - 2033 (USD Billion)
  • Table 8 North America biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 9 North America biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 10 North America biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 11 US biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 12 US biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 13 US biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 14 Canada biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 15 Canada biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 16 Canada biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 17 Mexico biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 18 Mexico biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 19 Mexico biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 20 Europe biosimilars market, by country, 2021 - 2033 (USD Billion)
  • Table 21 Europe biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 22 Europe biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 23 Europe biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 24 UK biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 25 UK biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 26 UK biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 27 Germany biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 28 Germany biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 29 Germany biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 30 France biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 31 France biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 32 France biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 33 Italy biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 34 Italy biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 35 Italy biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 36 Spain biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 37 Spain biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 38 Spain biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 39 Norway biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 40 Norway biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 41 Norway biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 42 Denmark biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 43 Denmark biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 44 Denmark biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 45 Sweden biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 46 Sweden biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 47 Sweden biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 48 Asia Pacific biosimilars market, by country, 2021 - 2033 (USD Billion)
  • Table 49 Asia Pacific biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 50 Asia Pacific biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 51 Asia Pacific biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 52 Japan biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 53 Japan biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 54 Japan biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 55 China biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 56 China biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 57 China biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 58 India biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 59 India biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 60 India biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 61 Australia biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 62 Australia biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 63 Australia biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 64 South Korea biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 65 South Korea biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 66 South Korea biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 67 Thailand biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 68 Thailand biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 69 Thailand biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 70 Latin America biosimilars market, by country, 2021 - 2033 (USD Billion)
  • Table 71 Latin America biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 72 Latin America biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 73 Latin America biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 74 Brazil biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 75 Brazil biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 76 Brazil biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 77 Argentina biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 78 Argentina biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 79 Argentina biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 80 Middle East & Africa biosimilars market, by country, 2021 - 2033 (USD Billion)
  • Table 81 Middle East & Africa biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 82 Middle East & Africa biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 83 Middle East & Africa biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 84 South Africa biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 85 South Africa biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 86 South Africa biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 87 Saudi Arabia biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 88 Saudi Arabia biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 89 Saudi Arabia biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 90 UAE biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 91 UAE biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 92 UAE biosimilars market, by end use, 2021 - 2033 (USD Billion)
  • Table 93 Kuwait biosimilars market, by drug class, 2021 - 2033 (USD Billion)
  • Table 94 Kuwait biosimilars market, by indication, 2021 - 2033 (USD Billion)
  • Table 95 Kuwait biosimilars market, by end use, 2021 - 2033 (USD Billion)

List of Figures

  • Fig. 1 Biosimilars market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and disease outlook (USD Billion)
  • Fig. 10 Competitive landscape
  • Fig. 11 Biosimilars market dynamics
  • Fig. 12 Biosimilars market: Porter's five forces analysis
  • Fig. 13 Biosimilars market: PESTLE analysis
  • Fig. 14 Drug Class market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 15 Monoclonal Antibodies (mAbs) Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 16 Growth Factors & Hematopoietic Agents Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 17 Insulin & Analogues Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 18 Osteoporosis / Bone Metabolism Agents Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 19 Others Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 20 Indication market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 21 Autoimmune Disorders (RA, IBD, Psoriasis, Ankylosing Spondylitis) market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 22 Oncology (Breast, Colorectal, Lymphoma, Lung, Gastric) market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 23 Diabetes Mellitus (Type 1 & Type 2) market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 24 Ophthalmic Disorders (Wet AMD, DME, RVO) market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 25 Hematologic / Rare Blood Disorders market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 26 Others market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 27 End Use market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 28 Hospitals market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 29 Specialty Pharmacies market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 30 Online & Retail Channels market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 31 Biosimilars market revenue, by region
  • Fig. 32 Regional marketplace: Key takeaways
  • Fig. 33 North America biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 34 U.S. country dynamics
  • Fig. 35 U.S. biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 36 Canada country dynamics
  • Fig. 37 Canada biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 38 Mexico country dynamics
  • Fig. 39 Mexico biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 40 Europe biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 41 UK country dynamics
  • Fig. 42 UK biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 43 Germany country dynamics
  • Fig. 44 Germany biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 45 France country dynamics
  • Fig. 46 France biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 47 Italy country dynamics
  • Fig. 48 Italy biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 49 Spain country dynamics
  • Fig. 50 Spain biosimilars market, 2021 - 2033 (USD Billion)
  • Fig. 51 Norway country dynamics
  • Fig. 52 Norway biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 53 Sweden country dynamics
  • Fig. 54 Sweden biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 55 Denmark country dynamics
  • Fig. 56 Denmark biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 57 Asia Pacific biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 58 Japan country dynamics
  • Fig. 59 Japan biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 60 China country dynamics
  • Fig. 61 China biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 62 India country dynamics
  • Fig. 63 India biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 64 Australia country dynamics
  • Fig. 65 Australia biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 66 South Korea country dynamics
  • Fig. 67 South Korea biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 68 Thailand country dynamics
  • Fig. 69 Thailand biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 70 Latin America biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 71 Brazil country dynamics
  • Fig. 72 Brazil biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 73 Argentina country dynamics
  • Fig. 74 Argentina biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 75 MEA biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 76 South Africa country dynamics
  • Fig. 77 South Africa biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 78 Saudi Arabia country dynamics
  • Fig. 79 Saudi Arabia biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 80 UAE country dynamics
  • Fig. 81 UAE biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 82 Kuwait country dynamics
  • Fig. 83 Kuwait biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 84 Company categorization
  • Fig. 85 Company market position analysis
  • Fig. 86 Strategic framework